HJLI yields 19.27% · JNJ yields 2.13%● Live data
📍 HJLI pulled ahead of the other in Year 1
Combined, HJLI + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of HJLI + JNJ for your $10,000?
Hancock Jaffe Laboratories, Inc. is a development stage medical device company, which develops tissue based solutions that are designed to be life sustaining or life enhancing for patients with cardiovascular disease, and peripheral arterial and venous disease. The company is headquartered in Irvine, California and currently employs 9 full-time employees. The firm is developing biologic-based solutions that are designed to be life enhancing for patients with cardiovascular disease, peripheral arterial and venous disease, and end stage renal disease (ESRD). The firm is in the process of developing bioprosthetic implantable devices for cardiovascular disease. The Company’s Bioprosthetic Heart Valve (BHV), is a bioprosthetic, pig heart valve designed to function like a native heart valve, and designed to provide a patient greater functional performance than available devices. The Company’s product Venous Valve is a bioprosthetic, pig venous valve for patients with lower limb chronic venous insufficiency (CVI), which occurs because of damage to the valves of the veins in the legs after patients develop blood clots in the deep venous system.
Full HJLI Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.